The Asia Pacific brain implants market was valued at US$ 1,346.12 million in 2022 and is expected to reach US$ 3,536.70 million by 2030; it is estimated to grow at a CAGR of 12.8% from 2022 to 2030.
Strategic Initiatives by Companies Fuels Asia Pacific Brain Implants Market
Companies operating in the brain implants market constantly focus on strategic developments such as product approvals, collaborations, expansions, agreements, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a greater than existing customer base. A few of the noteworthy developments in the brain implants market are mentioned below: In December 2022, Abbott launched the Eterna spinal cord stimulation (SCS) system, which is the smallest implantable, rechargeable SCS system available on the market for the treatment of chronic pain. The company's portfolio of neuromodulation devices also includes Proclaim XR, the recharge-free SCS system, and Proclaim Plus featuring FlexBurst360. Brain implant manufacturers are taking steps to expand their operations around the world and launch their products in different regions, which is expected to boost the market penetration and accessibility of their offerings. Therefore, product introduction and strategic moves such as approvals, expansions, and acquisitions create significant growth opportunities in the brain implants market.
Asia Pacific Brain Implants Market Overview
The Asia Pacific brain implants market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The factors driving the market growth include Key factors driving the market growth are surging prevalence of neurological disorders with increasing geriatric population and rising number of spinal cords injuries. However, high cost associated with brain implant devices and procedures hinders the market growth.
China is witnessing a growing demand for innovative therapies, such as brain implants, to address complex conditions such as Parkinson's disease and movement disorders. A 2020 study published in the BMJ Journal estimates that there are approximately 6 million Alzheimer's disease patients in China, with the proportion of those with dementia being 5%, 11.5%, and 30% among those aged 65, 75, and 85 years, respectively.
Asia Pacific Brain Implants Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Brain Implants Market Segmentation
The Asia Pacific brain implants market is segmented into treatment, application, end user, and country.
Based on treatment, the Asia Pacific brain implants market is classified into deep brain stimulation, spinal cord stimulation, vagus nerve stimulator, invasive and non-invasive brain-computer interface, responsive neurostimulation for seizures, auditory brainstem implant, and ophthalmic aid/implant. Further, the auditory brainstem implant segment is bifurcated into retrocochlear hearing impairment and cochlear hearing impairment. The spinal cord stimulation segment held the largest share in 2022.
In terms of application, the Asia Pacific brain implants market is categorized into chronic pain, Parkinson's disease, Alzheimer's disease, epilepsy, essential tremor, depression, dystonia, amyotrophic lateral sclerosis (ALS), and neurofibromatosis 2. The chronic pain segment held the largest share in 2022.
Based on end user, the Asia Pacific brain implants market is bifurcated into hospitals and specialized clinics/neurological centers. The hospitals segment held the largest share in 2022.
Based on country, the Asia Pacific brain implants market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific brain implants market in 2022.
Abbott Laboratories, Boston Scientific Corp, Medtronic Plc, NeuroSky Inc, Renishaw Plc, and Synchron Inc are some of the leading companies operating in the Asia Pacific brain implants market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,346.12 Million |
| Market Size by 2030 | US$ 3,536.70 Million |
| CAGR (2022 - 2030) | 12.8% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
1. Abbott Laboratories
2. Boston Scientific Corp
3. Medtronic Plc
4. NeuroSky Inc
5. Renishaw Plc
6. Synchron Inc
The Asia Pacific Brain Implants Market is valued at US$ 1,346.12 Million in 2022, it is projected to reach US$ 3,536.70 Million by 2030.
As per our report Asia Pacific Brain Implants Market, the market size is valued at US$ 1,346.12 Million in 2022, projecting it to reach US$ 3,536.70 Million by 2030. This translates to a CAGR of approximately 12.8% during the forecast period.
The Asia Pacific Brain Implants Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Brain Implants Market report:
The Asia Pacific Brain Implants Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Brain Implants Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Brain Implants Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Brain Implants Market
